This company seems to have been delisted
Reason: Acquired by Ipsen
Last recorded trade on: May 5, 2023
Source: https://www.ipsen.com/press-releases/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/
Reason: Acquired by Ipsen
Last recorded trade on: May 5, 2023
Source: https://www.ipsen.com/press-releases/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/
Albireo Pharma
ALBO
$76.80
Share price
0.00%
Change (1 day)
131.69%
Change (1 year)
Categories
Revenue for Albireo Pharma (ALBO)
Revenue in 2022 (TTM): NZ$87.71 Million
According to Albireo Pharma's latest financial reports the company's current revenue (TTM 
) is NZ$99.83 Million. In 2021 the company made a revenue of NZ$59.4 Million an increase over the revenue in the year 2020 that were of NZ$11.51 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Albireo Pharma from 2009 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | NZ$87.71 M | 47.65% |
| 2021 | NZ$59.4 M | 415.96% |
| 2020 | NZ$11.51 M | -19.52% |
| 2019 | NZ$14.3 M | -24.67% |
| 2018 | NZ$18.99 M | 1348790.08% |
| 2017 | NZ$0 M | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | |
| 2012 | N/A | |
| 2011 | N/A | |
| 2010 | N/A | |
| 2009 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | N/A | N/A | 🇺🇸 USA |